Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Efficacy of Interventions to Build Transition Readiness for Youth with Sickle Cell Disease: A 13-Year Evaluation of a Healthcare Transition Program

Melissa Azul, Tarun D Aurora, Shiela Anderson, Andrew M Heitzer, Jennifer Longoria, Martha Barton, Yunusa Olufadi, Guolian Kang, Ana Baumann, Jerlym S. Porter, Jane Hankins

Blood (2022) 140 (Supplement 1): 5139–5141.

https://doi.org/10.1182/blood-2022-169235

Published: 2022

Journal Articles

Comprehensive Nutrition Assessment in Adults with Sickle Cell Disease Using the Dietary Inflammatory Index and Healthy Eating Index

Lana Mucalo, Jane Hankins, Janelle Highland, Hamda Khan, Ashima Singh, Amanda M. Brandow

Blood (2022) 140 (Supplement 1): 11112–11113.

https://doi.org/10.1182/blood-2022-170461

Published: 2022

Journal Articles

Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo , CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction

Akshay Sharma, Jaap Jan Boelens, Maria I. Cancio, Jane Hankins, Prafulla A Bhad, Andrew Lewandowski, Xiaojun Zhao, Shripad Chitnis, Radhika Peddinti, Yan Zheng, Neena Kapoor, Fabio Ciceri, Jianping Yuan, Vionnie W. Yu, Susan C. Stevenson, Serena De Vita, James LaBelle

Blood (2022) 140 (Supplement 1): 1906–1908.

https://doi.org/10.1182/blood-2022-166254

Published: 2022

Journal Articles

Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)

Meghna Dua, Winfred C. Wang, R. Clark Brown, Melissa A. McNaull, Zora R. Rogers, Martha Barton, Jane Hankins, Jeffrey Gossett, Julie Richardson, Jerlym S. Porter, Guolian Kang, Jeremie H. Estepp

Blood (2022) 140 (Supplement 1): 445–446.

https://doi.org/10.1182/blood-2022-160485

Published: 2022

Journal Articles

Patient-Reported Outcomes Are Significantly Worse in Adults with Sickle Cell Disease Who Have Chronic Pain Compared to Those Who Do Not

Lana Mucalo, Jane Hankins, Janelle Highland, Hamda Khan, Ashima Singh, Amanda M. Brandow

Blood (2022) 140 (Supplement 1): 11137–11138.

https://doi.org/10.1182/blood-2022-167148

Published: 2022

Journal Articles

Mortality in Adults with Sickle Cell Disease: Results from the Sickle Cell Disease Implementation Consortium (SCDIC) Registry

Franklin Njoku, Norma Pugh, Marsha Treadwell, Jeffrey A. Glassberg, Abdullah Kutlar, Robert Gibson, Nirmish Shah, Victor R. Gordeuk, Lewis L. Hsu, Jane Hankins, Allison A. King, Julie Kanter

Blood (2022) 140 (Supplement 1): 2586–2588.

https://doi.org/10.1182/blood-2022-168856

Published: 2022

Journal Articles

Baseline Patient and Provider Reports of Quality of Care and Confidence Providing ED Management of Vaso-Occlusive Episodes

Paula Tanabe, Jane Hankins, Robert Gibson, Victor R. Gordeuk, Cathy L Melvin, Liliana Preiss, Lauren Siewny, Lynne Richardson, Marsha Treadwell, Allison A. King

Blood (2022) 140 (Supplement 1): 2570–2571.

https://doi.org/10.1182/blood-2022-158016

Published: 2022

Journal Articles

Hydroxyurea at Maximal Tolerated Dose (MTD) Prior to Completion of the β-Globin Switch Has Additive but Not Sustained Benefits in Fetal Hemoglobin Production

Christina Abrams, MD, Joseph Moen, MS, Guolian Kang, PhD, Winfred C. Wang, MD, Jane Hankins, MD MS, Jeremie H. Estepp, MD

Blood (2016) 128 (22): 125.

https://doi.org/10.1182/blood.V128.22.125.125

Published: 2016

Journal Articles

Agreement Between R2 and R2* Liver Iron Estimates Is Independent of the Type of Iron Removal Therapy: Results from the Twitch Trial

John C Wood, MD PhD, Tim St Pierre, PhD, Banu Aygun, MD, Nicole Mortier, PA-C, William H Schultz, MHS PA, Connie M. Piccone, MD, Jane Hankins, MD MS, Zora R. Rogers, MD, William Owen, MD, Isaac Odame, MBChB, FRCPath, FRCPC, Sharada A. Sarnaik, MD, Lee Hilliard, MD, Alan R. Cohen, MD, Russell E. Ware, MD PhD

Blood (2016) 128 (22): 1274.

https://doi.org/10.1182/blood.V128.22.1274.1274

Published: 2016

Journal Articles

Genetic Predictors of Hydroxyurea Response in Children with Sickle Cell Disease.

Jenny McDade, DO, MS, Jonathan M Flanagan, PhD, Nicole Mortier, MHS, PA-C, Matthew Smeltzer, MS, Thad A Howard, MS, Amy Cone, FNP, Jane Hankins, MD, MS, Banu Aygun, MD, Song Wu, PhD, Russell E Ware, MD, PhD

Blood (2009) 114 (22): 820.

https://doi.org/10.1182/blood.V114.22.820.820

Published: 2009

Journal Articles

Cardiac T2* Magnetic Resonance Imaging (MRI) in Iron Overload and Ventricular Diastolic Function.

Jane Hankins, MD, MS, Claudia Hillenbrand, PhD, Vijay Joshi, MD, Ralf Loeffler, PhD, Ruitian Song, PhD, Russell Ware, MD, PhD, Eileen Hansbury, PA-C, Martha Rieman, FNP, Nicole Mortier, MHS, PA-C, Matt Smeltzer, MS, Chin-Shang Li, PhD, M. Beth McCarville, MD

Blood (2007) 110 (11): 2676.

https://doi.org/10.1182/blood.V110.11.2676.2676

Published: 2007

Journal Articles

Phase I Study of Combination Treatment with Hydroxyurea and Magnesium Pidolate in Children with Sickle Cell Anemia.

Jane Hankins, MD, MS, Lynn Wynn, MSN, PNP, Carlo Brugnara, PhD, Cheryl Hillery, MD, Chin-Shang Li, PhD, Winfred Wang, MD

Blood (2006) 108 (11): 686.

https://doi.org/10.1182/blood.V108.11.686.686

Published: 2006

Journal Articles

Therapeutic Intervention and Decision-Making by Parents of Children with Severe Sickle Cell Anemia.

Jane Hankins, MD, MS, Sara Day, MSN, Yvonne Carroll, RN, Paula Naidu, MPH, Pam Hinds, RN, PhD, Chin-Shang Li, PhD, Winfred Wang, MD

Blood (2005) 106 (11): 3193.

https://doi.org/10.1182/blood.V106.11.3193.3193

Published: 2005

Journal Articles

Therapeutic Intervention and Decision-Making by Primary Caregivers of Children with Severe Sickle Cell Anemia.

Jane Hankins, MD, MS, Sara Day, RN, MSN, Yvonne Carroll, RN, JD, Paula Naidu, MPH, Chin-Shang Li, PhD, Pamela Hinds, RN, PhD, Patricia Garvie, PhD, Winfred Wang, MD

Blood (2004) 104 (11): 1661.

https://doi.org/10.1182/blood.V104.11.1661.1661

Published: 2004

NARROW

Efficacy of Interventions to Build Transition Readiness for Youth with Sickle Cell Disease: A 13-Year Evaluation of a Healthcare Transition Program

Comprehensive Nutrition Assessment in Adults with Sickle Cell Disease Using the Dietary Inflammatory Index and Healthy Eating Index

Treatment of Individuals with Severe Sickle Cell Disease with OTQ923, an Autologous, Ex Vivo , CRISPR/Cas9-Edited, CD34+ Hematopoietic Stem and Progenitor Cell Product, Leads to Durable Engraftment and Fetal Hemoglobin Induction

Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)

Patient-Reported Outcomes Are Significantly Worse in Adults with Sickle Cell Disease Who Have Chronic Pain Compared to Those Who Do Not

Mortality in Adults with Sickle Cell Disease: Results from the Sickle Cell Disease Implementation Consortium (SCDIC) Registry

Baseline Patient and Provider Reports of Quality of Care and Confidence Providing ED Management of Vaso-Occlusive Episodes

Hydroxyurea at Maximal Tolerated Dose (MTD) Prior to Completion of the β-Globin Switch Has Additive but Not Sustained Benefits in Fetal Hemoglobin Production

Agreement Between R2 and R2* Liver Iron Estimates Is Independent of the Type of Iron Removal Therapy: Results from the Twitch Trial

Genetic Predictors of Hydroxyurea Response in Children with Sickle Cell Disease.

Cardiac T2* Magnetic Resonance Imaging (MRI) in Iron Overload and Ventricular Diastolic Function.

Phase I Study of Combination Treatment with Hydroxyurea and Magnesium Pidolate in Children with Sickle Cell Anemia.

Therapeutic Intervention and Decision-Making by Parents of Children with Severe Sickle Cell Anemia.

Therapeutic Intervention and Decision-Making by Primary Caregivers of Children with Severe Sickle Cell Anemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only